Finally, it gained a high public profile when several groups extrapolated the preclinical data suggesting that treatment of cardiovascular patients with RAAS inhibitors (primarily chosen drugs in hypertension and heart failure) may result in an increase in serum ACE2 levels [6, 7, 26]. The gene discussed is ACE2; the disease is heart failure.